The use of opioids in chronic non-cancer pain (CNCP) is controversial, as it presents both benefits and risks. There is currently no available data on the incidence, prescription pattern, functional outcomes and adverse effects of opioids in patients with CNCP in Singapore. This study aimed to address the aforementioned deficit.
I NTRO D U C TIO N
Chronic pain is described as pain lasting for a duration of more than three months or persisting beyond the period of tissue healing.
(1) Chronic pain has a substantial impact on not only suffering individuals and their families, but also society in general. (2, 3) Traditionally, opioids have had a well-defined role in the management of cancer and acute pain. (4, 5) The effectiveness of opioids in cancer and acute pain management has prompted its use in chronic non-cancer pain (CNCP). Unfortunately, the liberal use of opioids in some countries has introduced a new set of problems, namely the misuse and diversion of opioids, dependence on opioids and death from overdose. (6) (7) (8) (9) This has prompted the publication of recommendations and guidelines by several international bodies, acknowledging the limited benefits of opioids in CNCP treatment and cautioning against the use of opioids due to its various associated complications. (10) (11) (12) (13) (14) In a survey conducted in 2008, the incidence of chronic pain in Singapore was reported to be 8.7%, (15) with a majority of these patients suffering from CNCP. However, there is a paucity of data on the use of opioids in patients with CNCP in Asian countries, and no data from Singapore is currently available. This study, which aimed to address this deficit, was conducted to determine the incidence, prescription pattern, functional outcomes and adverse effects of opioid use in this group of patients in Singapore.
M E TH O DS
Following institutional review board approval, all the records of patients seen at the Pain Management Centre, Singapore
General Hospital, Singapore, over a two-year period (between January 2006 and March 2008), who were prescribed strong opioids for the control of CNCP for a duration of more than three months in a year, were retrospectively analysed.
Information was gathered from written case records, direct communications with the pain physicians involved, pharmacy records and the hospital's electronic medical records, which are accessible to registered doctors at the hospital. Factors studied included type of opioids prescribed, indications for opioid prescription, uncontrolled side effects, and functional status with respect to the patient's ability to perform activities of daily living (ADL) and the ability to return to useful work. Coexisting psychological issues and aberrant drug-seeking behaviour while taking these strong opioids were also analysed. Pain scores were not determined prior to and after the commencement of opioids, as changes in functional status were thought to be more important outcomes than mere improvement of pain scores.
Strong opioids, for the purpose of this study, were defined as Class I drugs available in Singapore. These included morphine, methadone, oxycodone and fentanyl patch. Tramadol and codeine were excluded, as they are classified as weak opioids without significant dependence and abuse potential. Engagement in work included not only employment outside the home, but also the ability to perform work as a homemaker or provide useful assistance within the home. Work status was considered to have 'improved' if patients who were previously not engaged in work were able to do so after opioid therapy, while it was considered 'not improved' if patients were not engaged in work before and after opioid therapy. For patients who were already working prior to taking opioids and continued to work while on opioids, the work status was classified as 'unchanged'.
Problematic drug use or aberrant drug-seeking behaviour was assessed and defined based on the criteria described by Chabal et al (17) as follows: 
RESUlTS
A total of 42 non-cancer patients received strong opioids for more than three months in a year during the study period, accounting for 3.0% of new patients seen (n = 1,389) . The mean age of the 42 patients was 48 (range 24-81) years, and women comprised 42.9% of the patients. Table I shows the details of the patients' opioid therapy. The most commonly used opioid was methadone (45.2%), followed by morphine (38.1%), oxycodone (23.8%) and fentanyl patch (9.5%). The mean dose of morphine (or its dose equivalent) was 65 mg, while its median dose was 45 (range 9.4-300) mg. The most common diagnosis for which opioids were prescribed was spine-related pain (neuropathic and nociceptive), which accounted for 38.1% of patients. Other diagnoses for which opioids were prescribed included nonspinal neuropathic pain (19.0%), chronic postsurgical pain (11.9%), visceral pain (11.9%), headache (4.8%), post-trauma chronic pain (4.8%) and others (9.5%).
The four patients in the miscellaneous group had systemic sclerosis, ischaemic pain from an autoimmune disease, dermatitis artefacta and pain from a foreign body in the lung.
The distribution of opioids used within each diagnostic category is shown in Fig. 1 . Morphine was used in all categories, while methadone was used in all but one category, i.e.
patients with headaches. Dual opioid therapy was used in seven patients and the remaining patients received only one type of opioid. Among the 42 patients who received strong opioids, 10 had severe side effects that could not be controlled with medication -constipation despite taking laxatives (n = 6), significant dizziness and nausea (n = 3), and urinary retention complicated by urinary tract infection (n = 1).
The outcomes of ADL assessment and the impact that opioids had on the patients' return to work are summarised in 
D I SCU S S IO N
Our data revealed that about 3% of all patients seen at our pain clinic were given strong opioids for a period of at least three months in a year. However, our cohort consisted of patients who had come to a tertiary hospital with severe pain, having previously exhausted other modalities of treatment.
Direct comparison of our data with that of other countries is difficult, as most other studies have reported opioid use as a percentage of the population or in terms of the absolute dose of morphine taken over a period of time. Furthermore, our data was collected in a tertiary setting, whereas previous surveys on opioid prescription rates were taken from the general population. Nonetheless, in the United States, more than 3% of adults now receive long-term opioid therapy for CNCP. (7) Opioid prescription for musculoskeletal pain has doubled from 8% to 16% between 1980 and 2000. (18) According to a study by Caudill-Slosberg et al, the use of more potent opioids has increased from 2% to 9% of visits for musculoskeletal pain complaints. (18) In Denmark, an estimated 0.2% of the population was using opioids for chronic pain despite an estimated pain prevalence of 30%, although this study also included patients with cancer. (19) Bell reported that, in Australia, the amount of oral morphine consumed increased five-fold from 117 kg to 578 kg over a ten-year period from 1986 to 1996. (20) In our analysis, morphine and methadone were the most frequently prescribed opioids, accounting for about two-thirds of the total opioids used. Although oxycodone was officially approved for use in Singapore in 2005, its higher cost may have accounted for its lower usage in our cohort. In our study, dual opioid therapy was not commonly used for CNCP; it was mainly used for breakthrough pain and during conversion from one opioid to another.
Spine-related pain (38%) was the principal reason why opioids were prescribed for our patients. This finding was similar to that of two studies from small primary care centres. (21, 22) One study was by Reid et al; (21) the study, which involved patients with CNCP who received at least six months of opioid prescriptions, reported that low back pain (54%) and spinal stenosis (29%) accounted for most of the prescriptions.
The other study was study by Adams et al; (22) the study reported that spine-related pain or lower lumbar back pain (44%), joint disease/arthritis (33%) and headache/migraine pain (28%)
were the three most common reasons for opioid use. However, unlike our study, oxycodone was more frequently prescribed than morphine in these two studies.
Although intolerable side effects were seen in some of our patients, its incidence was surprisingly low. In our study, only 6 (14.3%) patients had significant constipation despite using laxatives. Other studies have shown bowel-related dysfunction from opioids to be as high as 63.5%, especially when morphine is used. (23) The lower prevalence in our study may be dosedependent, but this association was not evaluated in detail.
Also, we did not include patients who responded to simple laxatives. Despite medication, three patients reported significant dizziness and nausea, and one patient had opioid-induced urinary retention with urinary tract infection.
Established guidelines on the management of CNCP with opioids dictate that there should be demonstrable improvements in physical, psychological and social functions with opioid treatment. (10) (11) (12) In a large Danish Health and Morbidity Survey, (24) the authors analysed the results from a national random sample of 10,066 individuals, of whom 1,906 were identified as having CNCP. The study concluded that the use of opioids to manage CNCP did not fulfil opioid treatment goals, which included pain relief, improved quality of life and improved functional capacity. However, our study showed that about a quarter (n = 10) of patients were able to return to work after the initiation of opioids for pain control.
Another 14 patients were able to continue working after the initiation of opioid therapy and two patients, although retired,
were usefully occupied at home. Thus, a total of 26 (61.9%) patients with CNCP on active opioid treatment in our study were able to function without becoming an economic burden.
One-third of our patients did not return to useful work and one patient stopped working after initiating opioids, concurring with other reports that suggest that opioids do not always improve function. (13) Patients who remain refractory to long-term opioid therapy for chronic pain may have psychiatric disorders and major coexistent psychological issues that act as barriers to effectiveness. (25) About 30%-50% of patients presenting to chronic pain clinics meet the criteria for current major depression. In our study, aberrancy was seen in 5 (11.9%) patients. This result must be interpreted in the context of a study that was performed on a small sample visiting a tertiary centre. There is a paucity of literature on this subject from South Asia, and a study by Larance et al has noted that prescription medications abused in this region tend to be low-potency opioids. (27) A review by Højsted and Sjøgren reported the prevalence of problematic drug use (including addiction, abuse, misuse and dependence) to be 0%-50%. (28) Such variable prevalence rates were probably due to differences in definitions, study design and population samples. According to a survey of primary care
patients that adopted the Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) diagnostic criteria, the reported prevalence of opioid-use disorder was 34.9%. (29) The role of urinary drug testing (UDT) remains controversial.
UDT is the most practical and objective tool available to prescribers for medically assessing, at any given point in time, whether a patient is taking prescribed medications or unauthorised controlled medications, or using illicit substances. (30) 
In Singapore, opioid prescriptions have a strong framework created to prevent misuse. (32, 33) In line with international Repeated re-evaluation is made after the initiation of therapy.
h. Ensure accurate and meticulous record keeping.
A balance has to be struck between the widespread prevalence of chronic pain -19% in Europe, (3) 21% in the United Kingdom, (34) approximately 30% in the United States (35) and at least 8.7% in Singapore (15) -and the use of opioids for the management of patients with chronic pain. Concerns regarding addiction, diversion, misuse and intolerable side effects remain significant barriers to the prescription of opioids. (36, 37) Other than the weak evidence supporting the use of opioids for CNCP, (12) the long-term outcomes of its use are also uncertain. (10) However, recommendations by a panel of experts suggest that opioids can benefit a select group of patients with chronic pain, and if comprehensive risk assessment is performed, the benefits could outweigh potential harm. (14) Drawbacks of this study include its retrospective nature and the short time frame used for data collection, which could have been extended to include more patients. Also, functional assessment would have been more complete if standardised questionnaires such as the Short Form Health Survey 36 had been used. It would be interesting, going forward, to collect data to determine whether prescribing practices and the spectrum of adverse outcomes have changed in Singapore and how many of these patients continue to be on opioids.
In conclusion, the opioid prescription rate for CNCP was 3.0% over a two-year period at our centre. We found that opioids helped improve the ability of about one-third of our patients to perform ADL and enabled a quarter of our patients to return to work. Uncontrollable side effects were seen in a quarter of patients on opioid therapy and aberrant drug- 
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